Not looking goodIn their April 13 NR they state that they "commenced work with two, third-party laboratories to prepare validation protocols" so with today's NR does that mean that BOTH labs were unable to achieve a response from inert virus samples? If so, that is not promising, especially if using this type of pre-treated viral samples is standard of testing in validation laboratories. I would imagine if the test cannot positively identify an inert isolated antigen, how accurately could it identify live antigen when combined with other active endogenous and exogenous cells that one might expect to find from a live specimen.
In regards to the live patient sampling and testing within a hospital setting, why would they not have the independent labs or hospital conduct further trials of these sample types concurrent to the other testing as this would seem to be the gold standard for determining viability in a clinical setting. Seems like a mismanagement of time, especially when issue a statement: "coupled with previous hospital-based experiments, have suggested that testing using a live viral culture and/or patient sampling will be required for ultimate confirmation of the effectiveness of the Sona test." - - common sense, no?
Companies are trying to get these tests out asap and this just looks like they're dragging their feet or worse, do not have an effective test.